ABSTRACT
This article provides information about a scientific study conducted to explore the possibility of using photohemotherapy (UV blood irradiation) to correct hemostasis in the complex treatment of the SARS-CoV-2 coronavirus. The study included 21 patients diagnosed with SARS-CoV-2. The patients consisted of two groups: the main group (11 people), in which ultraviolet exposure to the blood was carried out in combination with the basic therapy, and the control group (10 people), where the treatment was used in accordance with the generally accepted basic therapy. The dynamics of stabilization of the parameters of the hemostasis system, the normalization of the acid-base durability of the blood, and the maximum saturation of erythrocyte hemoglobin were evaluated in comparison with the treatment results of patients in the control group. It was established that in patients with COVID-19 who underwent basic therapy in combination with intravenous UV irradiation of blood, in addition to improvement in the condition of the above systems, the following were noted: healing in CT scans of both lungs and negative PCR results in the study of swabs from the oropharynx and nasopharynx started 5-6 days earlier than in patients of the control group. Patients of the main group can be discharged after normalization of vital functions, CT scan of the lungs, and clinical and laboratory parameters 5-6 days earlier than patients in the control group.Copyright © 2022 Authors. All rights reserved.
ABSTRACT
This article provides information about a scientific study conducted to explore the possibility of using photohemotherapy (UV blood irradiation) to correct hemostasis in the complex treatment of the SARS-CoV-2 coronavirus. The study included 21 patients diagnosed with SARS-CoV-2. The patients consisted of two groups: the main group (11 people), in which ultraviolet exposure to the blood was carried out in combination with the basic therapy, and the control group (10 people), where the treatment was used in accordance with the generally accepted basic therapy. The dynamics of stabilization of the parameters of the hemostasis system, the normalization of the acid-base durability of the blood, and the maximum saturation of erythrocyte hemoglobin were evaluated in comparison with the treatment results of patients in the control group. It was established that in patients with COVID-19 who underwent basic therapy in combination with intravenous UV irradiation of blood, in addition to improvement in the condition of the above systems, the following were noted: healing in CT scans of both lungs and negative PCR results in the study of swabs from the oropharynx and nasopharynx started 5-6 days earlier than in patients of the control group. Patients of the main group can be discharged after normalization of vital functions, CT scan of the lungs, and clinical and laboratory parameters 5-6 days earlier than patients in the control group.Copyright © 2022 Authors. All rights reserved.
ABSTRACT
This article provides information about a scientific study conducted to explore the possibility of using photohemotherapy (UV blood irradiation) to correct hemostasis in the complex treatment of the SARS-CoV-2 coronavirus. The study included 21 patients diagnosed with SARS-CoV-2. The patients consisted of two groups: the main group (11 people), in which ultraviolet exposure to the blood was carried out in combination with the basic therapy, and the control group (10 people), where the treatment was used in accordance with the generally accepted basic therapy. The dynamics of stabilization of the parameters of the hemostasis system, the normalization of the acid-base durability of the blood, and the maximum saturation of erythrocyte hemoglobin were evaluated in comparison with the treatment results of patients in the control group. It was established that in patients with COVID-19 who underwent basic therapy in combination with intravenous UV irradiation of blood, in addition to improvement in the condition of the above systems, the following were noted: healing in CT scans of both lungs and negative PCR results in the study of swabs from the oropharynx and nasopharynx started 5-6 days earlier than in patients of the control group. Patients of the main group can be discharged after normalization of vital functions, CT scan of the lungs, and clinical and laboratory parameters 5-6 days earlier than patients in the control group.Copyright © 2022 Authors. All rights reserved.
ABSTRACT
Methylene blue (MB) is a well-known pharmaceutical ingredient that is thought to have a multi-targeted therapeutic effect as an anti-malarial and neuroprotective agent and has recently been identified as a treatment for coronavirus disease 2019 (COVID-19). In this review, we present an overview of relevant clinical trials, including ongoing trials, on the therapeutic uses of MB. A search for clinical trials on clinicaltrials.gov was performed using the terms "methylene blue" and "methylthionine chloride." This review focuses on clinical trials of MB-based therapies applied to brain diseases, cancer imaging and diagnosis, infectious diseases such as malaria or COVID-19, and cardiovascular diseases. Nanoparticle-based delivery techniques have also been briefly discussed in addition to common delivery methods.
ABSTRACT
In 2019, a new coronavirus (COVID-19) was discovered in Wuhan, China, which soon spread all over the world. The main hallmark of the disease includes fever, diarrhea, vomiting, and dry cough with dyspnea in half of the patients and acute respiratory distress syndrome (ARDS). Currently, no definitive treatment or prevention therapy exists for COVID-19 but scientists and researchers all over the world are relentlessly working to understand COVID-19 to discover novel therapeutic tools and vaccines. Today, photodynamic therapy (PDT) has been investigated as a noninvasive therapy for the treatment of this pandemic and was able to increase the healing process with the help of appropriate photosensitizers by targeting the pathogen inside the patient's body. Copyright © 2022, Semnan University of Medical Sciences. All rights reserved.
ABSTRACT
Curcumin (CUR) is a natural substance extracted from turmeric that has antimicrobial properties. Due to its ability to absorb light in the blue spectrum, CUR is also used as a photosensitizer (PS) in antimicrobial Photodynamic Therapy (aPDT). However, CUR is hydrophobic, unstable in solutions, and has low bioavailability, which hinders its clinical use. To circumvent these drawbacks, drug delivery systems (DDSs) have been used. In this review, we summarize the DDSs used to carry CUR and their antimicrobial effect against viruses, bacteria, and fungi, including drug-resistant strains and emergent pathogens such as SARS-CoV-2. The reviewed DDSs include colloidal (micelles, liposomes, nanoemulsions, cyclodextrins, chitosan, and other polymeric nanoparticles), metallic, and mesoporous particles, as well as graphene, quantum dots, and hybrid nanosystems such as films and hydrogels. Free (non-encapsulated) CUR and CUR loaded in DDSs have a broad-spectrum antimicrobial action when used alone or as a PS in aPDT. They also show low cytotoxicity, in vivo biocompatibility, and improved wound healing. Although there are several in vitro and some in vivo investigations describing the nanotechnological aspects and the potential antimicrobial application of CUR-loaded DDSs, clinical trials are not reported and further studies should translate this evidence to the clinical scenarios of infections.